Published in Cardiovascular Device Liability Week, April 2nd, 2006
Some of these questions, says Greely, focus on ethical issues related to donors. For example, given the long life span of human embryonic stem cell lines, and their likely use in clinical practice, will it really be possible to promise donors anonymity' "It seems highly likely," says Greely, "that the Food and Drug Administration will want as much information as possible about the donor's health, not only with regard to pathogens that may infect...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.